Anne Andersson
A5076091991- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Medical Imaging Techniques and Applications
- Advanced Breast Cancer Therapies
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Nutritional Studies and Diet
- Chemotherapy-induced cardiotoxicity and mitigation
- Alcohol Consumption and Health Effects
- Medication Adherence and Compliance
- Cancer Immunotherapy and Biomarkers
- Ovarian cancer diagnosis and treatment
- Cardiac tumors and thrombi
- Cancer, Lipids, and Metabolism
- Growth Hormone and Insulin-like Growth Factors
- Global Cancer Incidence and Screening
- Abdominal Trauma and Injuries
- Chronic Lymphocytic Leukemia Research
- Multiple and Secondary Primary Cancers
- Hepatocellular Carcinoma Treatment and Prognosis
- Statistical Methods in Clinical Trials
Umeå University
2012-2024
University of Copenhagen
2023
Danish Cancer Society
2014-2023
University Hospital of Umeå
2020-2023
Rigshospitalet
2021
Fondazione IRCCS Istituto Nazionale dei Tumori
2014
Prevention Institute
2014
Cancer Research Center
2014
Institute of Cancer Research
2014
Radboud University Medical Center
2014
Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free (DRFS) hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of prespecified primary outcome analysis an additional analysis.This global, phase III,...
We prospectively evaluated fat intake as predictor of developing breast cancer (BC) subtypes defined by estrogen receptor (ER), progesterone (PR), and human epidermal growth factor 2 (HER2), in a large (n = 337327) heterogeneous cohort women, with 10062 BC case patients after 11.5 years, estimating hazard ratios (HRs) Cox proportional modeling. High total saturated were associated greater risk ER+PR+ disease (HR 1.20, 95% confidence interval [CI] 1.00 to 1.45; HR 1.28, CI 1.09 1.52; highest...
Breast cancer is the most common among women and prevention strategies are needed to reduce incidence worldwide. A healthy lifestyle index score (HLIS) was generated investigate joint effect of modifiable factors on postmenopausal breast risk. The study included 242,918 from multinational European Prospective Investigation into Cancer Nutrition (EPIC) cohort, with detailed information diet assessed at baseline. HLIS constructed five (diet, physical activity, smoking, alcohol consumption...
Women with a diagnosis of breast cancer are at increased risk second primary cancers, and the identification factors for latter may have clinical implications. We followed-up 11 years 10,045 women invasive from European cohort, identified 492 including 140 contralateral cancers. Expected observed cases Standardized Incidence Ratios (SIR) were estimated using Aalen-Johansen Markovian methods. Information on various was obtained detailed questionnaires anthropometric measurements. Cox...
The association of reproductive factors with hormone receptor (HR)-negative breast tumors remains uncertain. Within the EPIC cohort, Cox proportional hazards models were used to describe relationships (menarcheal age, time between menarche and first pregnancy, parity, number children, age at last pregnancies, since full-term childbirth, breastfeeding, menopause, ever having an abortion use oral contraceptives [OC]) risk ER-PR- (n = 998) ER+PR+ 3,567) tumors. A later childbirth was associated...
Physical activity is associated with reduced risks of invasive breast cancer. However, whether this holds true for cancer subtypes defined by the estrogen receptor (ER) and progesterone (PR) status controversial. The study included 257,805 women from multinational EPIC-cohort detailed information on occupational, recreational household physical important cofactors assessed at baseline. During 11.6 years median follow-up, 8,034 incident cases were identified. Data ER, PR combined ER/PR...
Associations of breast cancer overall with indicators exposures during puberty are reasonably well characterized; however, uncertainty remains regarding the associations height, leg length, sitting height and menarcheal age hormone receptor-defined malignancies. Within European Prospective Investigation into Cancer Nutrition cohort, Cox proportional hazards models were used to describe relationships adult length at menarche risk estrogen progesterone receptor negative (ER-PR-) (n = 990)...
Results from prospective studies on premenopausal serum hormone levels in relation to breast cancer risk have been inconclusive, especially with regard tumor subtypes. Using a case–control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (801 cases 1,132 matched control subjects), we analyzed relationships of prediagnostic estradiol, free progesterone, testosterone, testosterone sex hormone-binding globulin (SHBG) by estrogen progesterone...
Long-term weight gain (i.e., since age 20) has been related to higher risk of postmenopausal breast cancer, but a lower premenopausal cancer. The effect change in middle adulthood is unclear. We investigated the association between women aged 40–50 years) and cancer before after 50. included female participants European Prospective Investigation into Cancer Nutrition cohort, with information on anthropometric measures at recruitment median follow-up 4.3 years. Annual was categorized using...
<h3>Importance</h3> Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential T-DM1 as monotherapy so far unknown. <h3>Objective</h3> To assess pathologic complete (pCR) standard therapy combination docetaxel, trastuzumab, pertuzumab (DTP) vs in patients with ERBB2 (formerly HER2)-positive cancer. <h3>Design, Setting, Participants</h3> This randomized phase 2 trial, conducted at 9 sites...
Experimental evidence shows cross‐talk in mammary cells between estrogen, insulin‐like growth factor I (IGF‐I) and their respective receptors possible synergistic effects of estrogen receptor (ER) activation increased IGF‐I signaling with regard to breast tumor development, epidemiological suggests that circulating levels may be related more the risk ER‐positive than ER‐negative cancer. Using a case–control study nested within prospective European EPIC cohort (938 cancer cases 1,394 matched...
Abstract Purpose: PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response (pCR) did not differ between the two groups. Here, we present survival outcomes from investigate metabolic tumor-infiltrating lymphocytes (TIL) as prognostic factors. Patients Methods: In total, 202 patients cancer were enrolled 197 received six cycles...
Experimental evidence suggests that vitamin D might play a role in the development of breast cancer. Although results case-control studies indicate circulating 25-hydroxyvitamin [25(OH)D] is inversely associated with risk cancer, prospective are inconsistent. A study embedded European Prospective Investigation into Cancer and Nutrition (EPIC) was carried out comprising 1,391 incident cancer cases controls. Multivariable conditional logistic regression models did not reveal significant...
The safety of local estrogen therapy in patients on adjuvant endocrine treatment is questioned, but evidence the issue scarce. This nested case-control registry-based study aimed to investigate whether affects breast cancer mortality risk women treatment.In a cohort 15,198 diagnosed with early hormone receptor (HR)-positive and treatment, 1262 died due were identified as cases. Each case was matched 10 controls. Exposure concurrent use aromatase inhibitors (AIs), tamoxifen, or both...
Genetic polymorphisms in vitamin D metabolism and signaling genes have been inconsistently associated with risk of breast cancer, though few studies examined SNPs D-related other than the receptor (VDR) gene particularly not association retinoid X alpha (RXRA) which may be a key pathway gene. We conducted nested case-control study 734 cases 1435 individually matched controls from population-based prospective cohort study, Northern Sweden Mammary Screening Cohort. Tag functional were...
Previous studies have shown increased cardiovascular mortality as late side effects in Hodgkin lymphoma (HL) patients. This study identifies stratifying risk factors for surveillance and defines concepts a clinical feasible noninvasive prospective protocol intervention of effects. HL patients diagnosed between 1965 1995 (n = 6.946) their first-degree relatives (FDR) were identified through the Swedish Cancer Registry Multigeneration Registry. For FDR cohort, in-patient care disease (CVD) was...
JCO
501 Background: Neoadjuvant therapy produces high rates of pathological complete response (pCR) and is the standard care in HER2 positive breast cancer; however, optimal treatment regimen remains to be established. Methods: In this randomized phase II study patients ≥18 years with cancer > 20mm or verified lymph node metastases were 6 courses docetaxel, trastuzumab pertuzumab (DTP, group A) emtansine (T-DM1, B), q 21 days. The protocol allowed switch competing upon lack drug-related...
The benefit of liver resection or ablation for breast cancer metastases (BCLM) remains unclear. aim the study was to determine survival after isolated BCLM in nationwide cohorts and compare surgical versus systemic treatment regimens.The Swedish register bile ducts (SweLiv) National (NBCR) studied identify patients with 1-5 without extrahepatic spread diagnosed 2009-2016. Data from registers were validated completed by review medical records. A Kaplan-Meier plot log rank test used analyse...
To analyze differences between screen-detected and non-screen-detected invasive breast cancers by tumour characteristics age at diagnosis in the nationwide population-based mammography screening program Sweden.